Pfizer has entered into a multi-year partnership with Cartography Biosciences, a biotechnology company based in California, to identify new targets for cancer drugs. The agreement involves Cartography using its proprietary technology platforms, ATLAS and SUMMIT, to discover and validate tumor-selective antigens. These platforms analyze the expression of antigens in both healthy and tumor cells to find those that are specific to various types of cancer.
According to the terms of the deal, Pfizer will pay Cartography up to $65 million in upfront and near-term milestone payments, as well as option exercise fees. If all milestones are achieved, Cartography could receive over $800 million more in development, regulatory, and commercial payments. Additionally, Cartography will be eligible for tiered royalties on net sales from any successful programs resulting from this collaboration.
Cartography will lead the discovery and validation process for novel antigens. Once identified, Pfizer will select which antigens it wants to advance into further drug development. From there, Pfizer will handle all aspects of developing these candidates through regulatory approval and commercialization. Details about how many programs may come out of this partnership or which types of cancer Pfizer intends to target were not disclosed.
This agreement is part of a broader trend by Pfizer toward increased dealmaking activity in recent months. In late 2025, Pfizer was involved in a competitive bidding process with Novo Nordisk over Metsera, an obesity-focused biotech company. After several rounds of bids—including one from Novo Nordisk at $10 billion—Pfizer secured Metsera with a final offer of $9.8 billion.
In December 2025, Pfizer announced another major partnership by committing $1.9 billion with YaoPharma in China for an early-stage GLP-1 drug candidate (https://www.biospace.com/article/pfizer-partners-with-yaopharma-on-glp-1-drug-in-1-9b-deal/). Shortly afterward on December 15th, Pfizer entered two licensing agreements with Adaptive Biotechnologies related to immune diseases; one involved nearly $890 million in upfront and milestone payments (https://www.biospace.com/article/pfizer-and-adaptive-biotechnologies-sign-two-non-exclusive-licensing-agreements-for-immune-diseases/).
The financial details highlight both companies’ ongoing interest in advancing innovative therapies for serious conditions such as cancer while leveraging advanced biotechnological approaches.
